Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Five Star Equities Issues New Research Reports on CGIX, OMED, STML and TTI

TTI, BIOGY

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Cancer Genetics Inc. (NASDAQ: CGIX) shares jumped 10.72 percent to close at $18.69 a share Tuesday. The stock traded between $17.00 and $19.35 on volume of 553,395 shares traded. The company announced an exclusive multi-year agreement with Roche Servicios S.A. to expand molecular diagnostic cancer testing in Central America and the Caribbean. Shares of Cancer Genetics are up approximately 35.0 percent year-to-date.

Get more information on Cancer Genetics and free access to the in-depth equity report at:
www.FiveStarEquities.com/CGIX

Oncomed Pharmaceuticals Inc. (NASDAQ: OMED) shares spiked 13.70 percent to close at $35.78 a share Tuesday. The stock traded between $32.50 and $37.00 on volume 750,972 shares traded. Mizuho analysts have recently initiated coverage on the company with a “buy” rating. Shares of Oncomed Pharmaceuticals are up approximately 20.0 percent year-to-date.

Get more information on Oncomed Pharmaceuticals free access to the in-depth equity report at:
www.FiveStarEquities.com/OMED

Stemline Therapeutics Inc. (NASDAQ: STML) shares surged 17.48 percent to close at $28.77 a share Tuesday. The stock traded between $24.58 and $29.85 on volume of 685,850 shares traded. The company presented at the 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference on Tuesday and is scheduled to present at the Leerink Global Healthcare Conference on Thursday, February 13th. Shares of Stemline Therapeutics are up approximately 45.0 percent year-to-date.

Get more information on Stemline Therapeutics and free access to the in-depth equity report at:
www.FiveStarEquities.com/STML

TETRA Technologies, Inc. (NYSE: TTI) shares gained 12.61 percent to close at $11.34 a share Tuesday. The stock traded between $10.56 and $11.44 on volume 1.81 million shares traded. The company announced that it expects an increase of 37.0 percent in adjusted earnings per share for 2014. Shares of TETRA Technologies are down approximately 8.0 percent year-to-date.

Get more information on TETRA Technologies and free access to the in-depth equity report at:
www.FiveStarEquities.com/TTI

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today